These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23576010)

  • 1. [Fungal infections in hematology patients and after blood stem cell transplantation: prophylaxis and treatment].
    Egerer G; Schmitt T
    Med Klin Intensivmed Notfmed; 2014 Oct; 109(7):526-30. PubMed ID: 23576010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution.
    Tzadok R; Shapira MY; Moses AE; Or R; Block C; Strahilevitz J
    Mycoses; 2015 Dec; 58(12):694-8. PubMed ID: 26429354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
    Ping B; Zhu Y; Gao Y; Yue C; Wu B
    Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of new antifungal agents in prophylaxis of mycoses in high risk patients.
    van Burik JA
    Curr Opin Infect Dis; 2005 Dec; 18(6):479-83. PubMed ID: 16258319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine versus selective antifungal administration for control of fungal infections in patients with cancer.
    Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD000026. PubMed ID: 25188768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal prophylaxis for invasive mycoses in high risk patients.
    Ullmann AJ; Cornely OA
    Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
    Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis of fungal infections in haematological patients: contra].
    Schwartz S
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1871. PubMed ID: 20842608
    [No Abstract]   [Full Text] [Related]  

  • 15. Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B
    Transplant Proc; 2013; 45(1):407-14. PubMed ID: 23375330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].
    Sawada A; Sakata N; Higuchi B; Takeshita Y; Ishihara T; Sakata A; Kouroki M; Kondo O; Koyama M; Hirano S; Yasui M; Inoue M; Yoshioka A; Kawa K
    Rinsho Ketsueki; 2009 Dec; 50(12):1692-9. PubMed ID: 20068276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
    Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
    J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
    Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
    Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.